Activator protein-1 (AP-1) inhibition prevents endothelial to mesenchymal transition in diabetes-associated atherosclerosis: a translational study

Key Points

Inhibition of AP-1 significantly reduces endothelial to mesenchymal transition, preventing atherosclerosis.
The treatment led to a notable decrease in atherosclerosis indicators in diabetic models with human serum involved.
Observational analysis using human serum highlighted the relevancy and potential for clinical application of these findings.
Implications support further exploration of AP-1 as a therapeutic target in diabetes-related vascular diseases.

Abstract

This study identifies AP-1 inhibition with T-5224 as a potential therapeutic approach for EndMT resulting in reduced atherosclerosis in diabetes. The use of human serum underscores the translational relevance of these findings.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Khan et al. (Thu,) studied this question.

synapsesocial.com/papers/69a75c00c6e9836116a24518 https://doi.org/https://doi.org/10.1186/s12933-025-03060-5

Bookmark

View Full Paper